NASDAQ:MRSNMersana Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mersana Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $20.66 +0.78 (+3.92 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$19.53Now: $20.66▼$20.7250-Day Range$19.06MA: $21.53▼$23.4052-Week Range$1.32Now: $20.66▼$24.97Volume463,756 shsAverage Volume672,102 shsMarket Capitalization$1.38 billionP/E RatioN/ADividend YieldN/ABeta2.64 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Its lead product candidate is XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, non small cell lung cancer, and other orphan indications. Mersana Therapeutics, Inc. has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingMersana Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.75, Mersana Therapeutics has a potential upside of 20.6% from its current price of $20.53.Amount of Analyst CoverageMersana Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesMersana Therapeutics has received 220 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMersana Therapeutics has received 189 “underperform” votes. (Add your “underperform” vote.)Community SentimentMersana Therapeutics has received 53.79% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote “Outperform” if you believe MRSN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMersana Therapeutics does not currently pay a dividend.Dividend GrowthMersana Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mersana Therapeutics insiders have sold 205.55% more of their company's stock than they have bought. Specifically, they have bought $24,901.00 in company stock and sold $76,084.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Mersana Therapeutics is held by insiders.Percentage Held by Institutions59.93% of the stock of Mersana Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mersana Therapeutics are expected to grow in the coming year, from ($1.23) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mersana Therapeutics is -14.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mersana Therapeutics is -14.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMersana Therapeutics has a P/B Ratio of 12.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRSN Previous Symbol CUSIPN/A CIK1442836 Webwww.mersana.com Phone617-498-0020Debt Debt-to-Equity Ratio0.24 Current Ratio4.59 Quick Ratio4.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.12 million Price / Sales32.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.64 per share Price / Book12.60Profitability EPS (Most Recent Fiscal Year)($0.65) Net Income$-28,210,000.00 Net Margins-6,099.64% Return on Equity-78.18% Return on Assets-57.74%Miscellaneous Employees86 Outstanding Shares66,950,000Market Cap$1.38 billion Next Earnings Date8/7/2020 (Confirmed) OptionableNot Optionable $20.66 +0.78 (+3.92 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MRSN News and Ratings via Email Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions How has Mersana Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Mersana Therapeutics' stock was trading at $6.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRSN shares have increased by 220.0% and is now trading at $20.67. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Mersana Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mersana Therapeutics. When is Mersana Therapeutics' next earnings date? Mersana Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Mersana Therapeutics. How can I listen to Mersana Therapeutics' earnings call? Mersana Therapeutics will be holding an earnings conference call on Friday, August 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Mersana Therapeutics' earnings last quarter? Mersana Therapeutics Inc (NASDAQ:MRSN) released its earnings results on Friday, May, 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.03. The company earned $0.01 million during the quarter, compared to the consensus estimate of $0.37 million. Mersana Therapeutics had a negative net margin of 6,099.64% and a negative return on equity of 78.18%. View Mersana Therapeutics' earnings history. What price target have analysts set for MRSN? 5 Wall Street analysts have issued 12-month target prices for Mersana Therapeutics' stock. Their forecasts range from $20.00 to $32.00. On average, they anticipate Mersana Therapeutics' share price to reach $24.75 in the next twelve months. This suggests a possible upside of 19.7% from the stock's current price. View analysts' price targets for Mersana Therapeutics. Has Mersana Therapeutics been receiving favorable news coverage? News coverage about MRSN stock has been trending somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mersana Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Mersana Therapeutics. Who are some of Mersana Therapeutics' key competitors? Some companies that are related to Mersana Therapeutics include Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Schrodinger (SDGR), Legend Biotech (LEGN), Myokardia (MYOK), Arrowhead Pharmaceuticals (ARWR), HYPERA S A/S (HYPMY), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Blueprint Medicines (BPMC) and Nektar Therapeutics (NKTR). View all competitors. What other stocks do shareholders of Mersana Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Amarin (AMRN), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Marinus Pharmaceuticals (MRNS), ImmunoGen (IMGN), vTv Therapeutics (VTVT), Advanced Micro Devices (AMD) and Clovis Oncology (CLVS). Who are Mersana Therapeutics' key executives? Mersana Therapeutics' management team includes the following people: Ms. Anna Protopapas, Pres, CEO & Director (Age 55)Mr. David A. Spellman, Chief Financial Officer (Age 42)Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)Mr. Mikhail Papisov Ph.D., Co-FounderMs. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications When did Mersana Therapeutics IPO? (MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Mersana Therapeutics' stock symbol? Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN." Who are Mersana Therapeutics' major shareholders? Mersana Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.89%), FNY Investment Advisers LLC (0.22%), SG Americas Securities LLC (0.03%), Strs Ohio (0.02%), Nisa Investment Advisors LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Mersana Therapeutics stock include Andrew A F Hack, Ashish Mandelia, Enterprise Associates 14 New, Lawrence M Alleva, Scott D Sandell and Timothy B Lowinger. View institutional ownership trends for Mersana Therapeutics. Which institutional investors are selling Mersana Therapeutics stock? MRSN stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Mersana Therapeutics company stock in the last year include Ashish Mandelia, and Scott D Sandell. View insider buying and selling activity for Mersana Therapeutics. Which institutional investors are buying Mersana Therapeutics stock? MRSN stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., FNY Investment Advisers LLC, Strs Ohio, Nisa Investment Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , and SG Americas Securities LLC. Company insiders that have bought Mersana Therapeutics stock in the last two years include Andrew A F Hack, Enterprise Associates 14 New, and Lawrence M Alleva. View insider buying and selling activity for Mersana Therapeutics. How do I buy shares of Mersana Therapeutics? Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mersana Therapeutics' stock price today? One share of MRSN stock can currently be purchased for approximately $20.67. How big of a company is Mersana Therapeutics? Mersana Therapeutics has a market capitalization of $1.38 billion and generates $42.12 million in revenue each year. The company earns $-28,210,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe. What is Mersana Therapeutics' official website? The official website for Mersana Therapeutics is www.mersana.com. How can I contact Mersana Therapeutics? Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
